Ingala et al. (2021) found that healthy non-demented population with positivity in phosphorylated tau (T +) showed cognitive dysfunction, especially in the memory domain, and non-demented adults with positivity in one or more AT(N) biomarkers (i.e., A+T−(N)−, A+T+(N)−, A+T−(N)+, and A+T+(N)+) displayed reduced volume in the amygdala, entorhinal cortex, and nucleus accumbens, showing an increase posterior cortical atrophy and cerebrovascular burden across the AD continuum profiles. The gene discussed is MAPT; the disease is Alzheimer disease.